检索结果-南通市图书馆

Gut microbiota,inflammatory bowel disease and colorectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第30期28卷 4053-4060页

作者： Ana Elisa Valencise Quaglio thais gagno grillo Ellen Cristina Souza De Oliveira Luiz Claudio Di Stasi Ligia Yukie Sassaki Departament of Biophysics and Pharmacology Sao Paulo State University(Unesp)Institute of BiosciencesBotucatu 18618-689Sao Paulo StateBrazil Department of Internal Medicine Sao Paulo State University(Unesp)Medical SchoolBotucatu 18618-686Sao Paulo StateBrazil

The gut microbiota is a complex community of microorganisms that inhabit the digestive tracts of humans,living in symbiosis with the ***,characterized by an imbalance between the beneficial and opportunistic gut microbiota,is associated with several gastrointestinal disorders,such as irritable bowel syndrome(IBS);inflammatory bowel disease(IBD),represented by ulcerative colitis and Crohn’s disease;and colorectal cancer(CRC).Dysbiosis can disrupt the mucosal barrier,resulting in perpetuation of inflammation and *** increase in some specific groups of harmful bacteria,such as Escherichia coli(***)and enterotoxigenic Bacteroides fragilis(ETBF),has been associated with chronic tissue inflammation and the release of pro-inflammatory and carcinogenic mediators,increasing the chance of developing CRC,following the inflammationdysplasia-cancer sequence in IBD ***,the aim of the present review was to analyze the correlation between changes in the gut microbiota and the development and maintenance of IBD,CRC,and IBD-associated *** with IBD and CRC have shown reduced bacterial diversity and abundance compared to healthy individuals,with enrichment of Firmicute sand *** bacteria are also associated with the onset and progression of CRC,such as Fusobacterium nucleatum,***,Enterococcus faecalis,Streptococcus gallolyticus,and *** research can evaluate the advantages of modulating the gut microbiota as preventive measures in CRC high-risk patients,directly affecting the prognosis of the disease and the quality of life of patients.

关键词： Gut microbiota Dysbiosis Ulcerative colitis Crohn’s disease Inflammatory bowel disease Colorectal cancer

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease:A review of the literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Cardiology 2023年第5期15卷 217-228页

作者： thais gagno grillo Caroline Ferreira da Silva Mazeto Pupo Silveira Ana Elisa Valencise Quaglio Renata de Medeiros Dutra Julio Pinheiro Baima Silmeia Garcia Zanati Bazan Ligia Yukie Sassaki Department of Internal Medicine Medical SchoolSão Paulo State UniversityBotucatuBotucatu 18618686Brazil Department of Biophysics and Pharmacology Institute of BiosciencesSão Paulo State UniversityBotucatuBotucatu 18618689Brazil

Tumor necrosis factor inhibitors(anti-TNFs)are widely used therapies for the treatment of inflammatory bowel diseases(IBD);however,their administration is not *** failure(HF),although rare,is a potential adverse event related to administration of these ***,the exact mechanism of development of HF remains ***αis found in both healthy and damaged *** effects are concentration-and receptor-dependent,promoting either cardio-protection or cardiomyocyte *** rat models with TNFαreceptor knockout showed increased survival rates,less reactive oxygen species formation,and improved diastolic left ventricle ***,clinical trials employing anti-TNF therapy to treat HF had disappointing results,suggesting abolishment of the cardioprotective properties of TNFα,making cardiomyocytes susceptible to apoptosis and ***,patients with IBD who have risk factors should be screened for HF before initiating anti-TNF *** review aims to discuss adverse events associated with the administration of anti-TNF therapy,with a focus on HF,and propose some approaches to avoid cardiac adverse events in patients with IBD.

关键词： Tumor necrosis factor inhibitors Inflammatory bowel disease Heart failure Adverse event TNFαreceptor

MicroRNA expression in inflammatory bowel disease-associated colorectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2021年第9期13卷 995-1016页

作者： thais gagno grillo Ana Elisa Valencise Quaglio Rodrigo Fedatto Beraldo Talles Bazeia Lima Julio Pinheiro Baima Luiz Claudio Di Stasi Ligia Yukie Sassaki Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618-686São PauloBrazil Department of Biophysics and Pharmacology São Paulo State University(Unesp)Institute of BiosciencesBotucatu 18618-689São PauloBrazil

MicroRNAs(miRNAs)are non-coding RNA molecules composed of 19–25 nucleotides that regulate gene expression and play a central role in the regulation of several immune-mediated disorders,including inflammatory bowel diseases(IBD).IBD,represented by ulcerative colitis and Crohn’s disease,is characterized by chronic intestinal inflammation associated with an increased risk of colorectal cancer(CRC).CRC is one of the most prevalent tumors in the world,and its main risk factors are obesity,physical inactivity,smoking,alcoholism,advanced age,and some eating habits,in addition to chronic intestinal inflammatory processes and the use of immunosuppressants administered to IBD *** studies have identified miRNAs associated with an increased risk of developing CRC in this *** identification of miRNAs involved in this tumorigenic process could be useful to stratify cancer risk development for patients with IBD and to monitor and assess ***,the present review aimed to summarize the role of miRNAs as biomarkers for the diagnosis and prognosis of IBD-associated *** the future,therapies based on miRNA modulation could be used both in clinical practice to achieve remission of the disease and restore the quality of life for patients with IBD,and to identify the patients with IBD at high risk for tumor development.

关键词： MicroRNA Colorectal cancer Inflammatory bowel disease Crohn's disease Ulcerative colitis Cancer Diagnosis Prognosis Targets

Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2021年第33期9卷 10382-10391页

作者： thais gagno grillo Luciana Rocha Almeida Rodrigo Fedatto Beraldo Mariana Barros Marcondes Diego Aparecido Rios Queiróz Daniel Luiz da Silva Rodrigo Quera Julio Pinheiro Baima Rogerio Saad-Hossne Ligia Yukie Sassaki Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618687São PauloBrazil Department of Pathology São Paulo State University(Unesp)Medical SchoolBotucatu 18618687São PauloBrazil Inflammatory Bowel Disease Program Digestive Disease Center Clínica Universidad de los AndesSantiago 7550000Chile

BACKGROUND Anti-tumor necrosis factor agents were the first biologic therapy approved for the management of Crohn's disease(CD).Heart failure(HF)is a rare but potential adverse effect of these *** objective of this report is to describe a patient with CD who developed HF after the use of *** SUMMARY A 50-year-old woman with a history of hypertension and diabetes presented with abdominal pain,diarrhea,and weight *** and enterotomography showed ulcerations,areas of stenosis and dilation in the terminal ileum,and thickening of the intestinal *** patient underwent ileocolectomy and the surgical specimen confirmed the diagnosis of stenosing *** patient started infliximab and azathioprine treatment to prevent post-surgical *** 6 mo after initiating infliximab therapy,the patient complained of dyspnea,orthopnea,and paroxysmal nocturnal dyspnea that gradually *** revealed biventricular dysfunction,moderate cardiac insufficiency,an ejection fraction of 36%,and moderate pericardial effusion,consistent with *** cardiac disease was considered an infliximab adverse effect and the drug was *** patient received treatment with diuretics for HF and showed improvement of symptoms and cardiac ***,the patient is using anti-interleukin for CD and is *** This reported case supports the need to investigate risk factors for HF in inflammatory bowel disease patients and to consider the risk-benefit of introducing infliximab therapy in such patients presenting with HF risk factors.

关键词： Heart failure Infliximab Anti-tumor necrosis factor therapy Crohn's disease Inflammatory bowel disease Case report